Medivation weakness a buying opportunity, says UBS UBS said Medivation weakness from the PREVAIL presentation is a buying opportunity and said its Q4 urology survey indicates topline PREVAIL data will drive robust utilization. Shares are Buy rated with a $93 price target.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.
Medivation downgraded to Neutral from Buy at Goldman Goldman Sachs downgraded Medivation to Neutral saying current share levels fairly value Xtandi's opportunities in prostate and breast cancer. Goldman raised its price target for shares to $110 from $90 and believes Medivation's fundamentals remain strong.
Medivation upgraded to Buy at Canaccord As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.